EquityZen Growth Technology Fund LLC - Series 1691
Raised
$331K
Investors
13
Min Invest
$2,619
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1691 is a Delaware pooled investment fund filed by EquityZen Advisors LLC and Philip Haslett, raising $331K from 13 investors under Rule 506(b) and Section 3(c)(1). The fund has a $3K minimum investment and is part of EquityZen's pre-IPO platform with over 1,800 related EDGAR entities.
This pre-IPO fund operates under the typical EquityZen series structure, using 506(b) private placement exemption and 3(c)(1) investment company exclusion. The $3K minimum investment reflects the platform's retail-accessible positioning, significantly lower than institutional pre-IPO vehicles which often require $100K+ minimums.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
